Revvity's sourcing strategy exhibits a high degree of concentration, with a total import value of $424,000 USD from India across nine shipments, encompassing four products across three therapeutic categories. The top five products imported include Protein ($150K), Diagnostic ($100K), Reagent ($100K), and Plasma ($74K), with the top three categories being Medical Devices & Diagnostics (47.2%), Nutritional Supplements (35.4%), and Other (17.4%). This concentration indicates a strategic focus on specific product categories and suppliers, which can offer benefits such as streamlined procurement processes and potentially better pricing.
However, this single-source dependency also presents risks, including supply chain disruptions due to geopolitical issues, regulatory changes, or supplier-specific challenges. The absence of alternative suppliers in Revvity's sourcing profile suggests a need for diversification to mitigate potential risks. The stability of the relationship with the sole Indian supplier, ADVY Chemical Private Limited, is critical. The fact that all shipments are sourced from this single supplier underscores the importance of maintaining a strong and reliable partnership to ensure uninterrupted supply.
